Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110


High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics.

Shen J, Xu R, Mai J, Kim HC, Guo X, Qin G, Yang Y, Wolfram J, Mu C, Xia X, Gu J, Liu X, Mao ZW, Ferrari M, Shen H.

ACS Nano. 2013 Nov 26;7(11):9867-80. doi: 10.1021/nn4035316. Epub 2013 Oct 18.


Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells.

Zhang M, Xu R, Xia X, Yang Y, Gu J, Qin G, Liu X, Ferrari M, Shen H.

Biomaterials. 2014 Jan;35(1):423-31. doi: 10.1016/j.biomaterials.2013.09.033. Epub 2013 Oct 5.


Bone marrow endothelium-targeted therapeutics for metastatic breast cancer.

Mai J, Huang Y, Mu C, Zhang G, Xu R, Guo X, Xia X, Volk DE, Lokesh GL, Thiviyanathan V, Gorenstein DG, Liu X, Ferrari M, Shen H.

J Control Release. 2014 Aug 10;187:22-9. doi: 10.1016/j.jconrel.2014.04.057. Epub 2014 May 10.


Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy.

Falamarzian A, Aliabadi HM, Molavi O, Seubert JM, Lai R, Uludağ H, Lavasanifar A.

J Biomed Mater Res A. 2014 Sep;102(9):3216-28. doi: 10.1002/jbm.a.34992. Epub 2013 Oct 25.


Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA.

Ma Y, Kowolik CM, Swiderski PM, Kortylewski M, Yu H, Horne DA, Jove R, Caballero OL, Simpson AJ, Lee FT, Pillay V, Scott AM.

ACS Chem Biol. 2011 Sep 16;6(9):962-70. doi: 10.1021/cb200176v. Epub 2011 Jul 26.


STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response.

Alshamsan A, Haddadi A, Hamdy S, Samuel J, El-Kadi AO, Uludağ H, Lavasanifar A.

Mol Pharm. 2010 Oct 4;7(5):1643-54. doi: 10.1021/mp100067u. Epub 2010 Sep 14.


Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo.

Das J, Das S, Paul A, Samadder A, Bhattacharyya SS, Khuda-Bukhsh AR.

Toxicol Lett. 2014 Mar 21;225(3):454-66. doi: 10.1016/j.toxlet.2014.01.009. Epub 2014 Jan 17.


The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine.

Alshamsan A, Hamdy S, Samuel J, El-Kadi AO, Lavasanifar A, Uludağ H.

Biomaterials. 2010 Feb;31(6):1420-8. doi: 10.1016/j.biomaterials.2009.11.003. Epub 2009 Nov 13.


Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy.

Xu R, Huang Y, Mai J, Zhang G, Guo X, Xia X, Koay EJ, Qin G, Erm DR, Li Q, Liu X, Ferrari M, Shen H.

Small. 2013 May 27;9(9-10):1799-808. doi: 10.1002/smll.201201510. Epub 2013 Jan 6.


Porous silicon microparticles for delivery of siRNA therapeutics.

Shen J, Wu X, Lee Y, Wolfram J, Yang Z, Mao ZW, Ferrari M, Shen H.

J Vis Exp. 2015 Jan 15;(95):52075. doi: 10.3791/52075.


Therapeutic effects of signal transducer and activator of transcription 3 siRNA on human breast cancer in xenograft mice.

Yang Z, Cai JH, Xie SJ, Li GX, Song WQ, Yan QH, Yan L, Zhang F.

Chin Med J (Engl). 2011 Jun;124(12):1854-61.


[Growth inhibition of breast cancer cells in vitro and in vivo by siRNA targeting signal transducers and activators of transcription 3].

Yang Z, Yan L, Zhang F, Yan QH, Song WQ, Wang FA, Cai JH.

Zhonghua Zhong Liu Za Zhi. 2010 Nov;32(11):819-24. Chinese.


Sustained small interfering RNA delivery by mesoporous silicon particles.

Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M.

Cancer Res. 2010 May 1;70(9):3687-96. doi: 10.1158/0008-5472.CAN-09-3931.


Captopril-polyethyleneimine conjugate modified gold nanoparticles for co-delivery of drug and gene in anti-angiogenesis breast cancer therapy.

Li M, Li Y, Huang X, Lu X.

J Biomater Sci Polym Ed. 2015;26(13):813-27. doi: 10.1080/09205063.2015.1057991. Epub 2015 Jul 13.


Delivery of gene targeting siRNAs to breast cancer cells using a multifunctional peptide complex that promotes both targeted delivery and endosomal release.

Bjorge JD, Pang A, Fujita DJ.

PLoS One. 2017 Jun 30;12(6):e0180578. doi: 10.1371/journal.pone.0180578. eCollection 2017.


Functional graphene oxide as a plasmid-based Stat3 siRNA carrier inhibits mouse malignant melanoma growth in vivo.

Yin D, Li Y, Lin H, Guo B, Du Y, Li X, Jia H, Zhao X, Tang J, Zhang L.

Nanotechnology. 2013 Mar 15;24(10):105102. doi: 10.1088/0957-4484/24/10/105102. Epub 2013 Feb 20.


CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.

Herrmann A, Priceman SJ, Swiderski P, Kujawski M, Xin H, Cherryholmes GA, Zhang W, Zhang C, Lahtz C, Kowolik C, Forman SJ, Kortylewski M, Yu H.

J Clin Invest. 2014 Jul;124(7):2977-87. doi: 10.1172/JCI73174. Epub 2014 Jun 2. Erratum in: J Clin Invest. 2015 Jun;125(6):2547. Swiderski, Piotr [Added].


Suppression of tumor invasion and migration in breast cancer cells following delivery of siRNA against Stat3 with the antimicrobial peptide PR39.

Tian W, Li B, Zhang X, Dang W, Wang X, Tang H, Wang L, Cao H, Chen T.

Oncol Rep. 2012 Oct;28(4):1362-8. doi: 10.3892/or.2012.1911. Epub 2012 Jul 13.


Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.

Varshosaz J, Farzan M.

World J Gastroenterol. 2015 Nov 14;21(42):12022-41. doi: 10.3748/wjg.v21.i42.12022. Review.

Supplemental Content

Support Center